


# Polycythemia Vera

## LOW-RISK PV PATIENTS ELIGIBLE FOR CYTOREDUCTION

Alessandro Maria **Vannucchi**, Paola **Guglielmelli**, Fabrizio **Pane**,  
Francesco **Passamonti**, Valerio **De Stefano**, Massimo **Breccia**, Elisabetta **Abruzzese**  
Francesca **Palandri**, Tiziano **Barbui**

# Low-risk PV patients eligible for cytoreduction




According to the indications of the European leukemia Net, start of cytoreductive therapy in low-risk patients:

1. Is recommended in patients with poor tolerance to phlebotomy, symptomatic progressive splenomegaly, and persistent leukocytosis
2. Should be considered in patients with progressive leukocytosis, extreme thrombocytosis, or inadequate hematocrit control
3. Can be considered in patients with high symptom burden and/or with uncontrolled cardiovascular risk factors

Also, high allele burden of the JAK2V617F mutation and high absolute neutrophil count have been associated with increased thrombotic risk and should be taken into account when establishing the indication for starting cytoreduction in PV





Il presente documento è il prodotto finale del progetto *Clinical Assessment of resistance and Intolerance to Hydroxyurea as Criteria for Second-line Treatment in patients with Polycythemia Vera*, condotto nel corso del 2023 e 2024 dal Working Party GIMEMA sulle Neoplasie Mieloproliferative Croniche.

EXPERT PANEL

Alessandro Maria **Vannucchi** (coordinatore)

Paola **Guglielmelli** (referente di progetto)

Fabrizio **Pane**

Francesco **Passamonti**

Valerio **De Stefano**

Massimo **Breccia**

Elisabetta **Abruzzese**

Francesca **Palandri**

Tiziano **Barbui**

---

Questo progetto è stato realizzato con il supporto non condizionante di **AOP Health**.

